By day 22, untreated mice show advanced tumor growth, while SV.IgGOX40.IL-12 treated mice show little or no MOSEC.Fluc.p11 tumors.Depletion of CD4 and CD8 T cells, however, diminishes SV.IgGOX40.IL-12 treatment (Figure 6B,C) indicating the importance of T cell immune response to the therapeutic process. Here, CD4 is linked to neoplasm.